What separates us from everything else on the planet? The answer is our immune system. Our bodies need protection from the hostile environment in which we reside and its multitude of microorganisms and toxins. We can't see these invaders and probably will not notice them until we are adversely affected but that doesn't lessen the impact they can have on us. While our initial lines of defense are the skin and mucous membranes that separate us from the environment, our real protection against them is our immune system.

In the simplest terms, the immune system has two functions: identify self from non-self and to destroy or eliminate non-self. This can only happen when the immune system and all its components function optimally. Complications arise when the body incorrectly identifies an invader and/or attacks ‘self’ (i.e., auto-immune diseases) or fails to identify an invader (or wrongly manufactured cell such as cancer). These abnormal responses are due to the combined, cumulative effects of poor nutrition, infection, trauma, toxicity or stress which leave the body unable to overcome the immune insult.

Medi-Rithm, LLC (MRL) is a Nevada LLC and is seeking a partner(s) to take an active position in the further development of the company. MRL has developed a diagnostic and prescriptive tool designed to aid physicians in the treatment of cancer and other diseases which exploit immune system weaknesses. Our premise, and limited clinical experience shows, that a comprehensive and integrated analysis of a wide variety of test results and other factors about the individual patient will produce a superior outcome in the treatment of each patient's disease.

MRL and its algorithm were established by Dr. Stoff based on his 22+ years of experience in the field of immunological treatments. The company has already developed a preliminary and focused version of its tool and is seeking funding for further research, development and expanded clinical verification of its proprietary algorithm.

While MRL's initial focus is on the most common cancers, we expect that our tool will find application across a broad range of cancers as well as other diseases (e.g. Hepatitis, auto-immune diseases, chronic fatigue syndrome etc.). A preliminary version of the tool has been used in the treatment of prostate cancer with significant results. MRL believes that its algorithm will consistently give practitioners better results than they are achieving now.